<?xml version="1.0" encoding="UTF-8"?>
<p id="par0145">By contrast to individual drugs, combinations of 2â€“3 BSAAs could be used to target an even broader range of viruses (
 <xref rid="bib0145" ref-type="bibr">Foucquier and Guedj, 2015</xref>, 
 <xref rid="bib0570" ref-type="bibr">Zheng et al., 2018</xref>). Such combinations could serve as front line therapeutics against poorly characterized emerging viruses or re-emerging drug-resistant viral strains. For example, a cocktail of nitazoxanide, favipiravir, and niclosamide could be developed for the treatment of viruses belonging to 11 families.
</p>
